Pfizer has decided not to divide itself into two companies, one focusing on older drugs and another on patent-protected products, according to the Wall Street Journal.

The FDA approved a new drug called Amjevita Sept. 23. The drug, adalimumab-atto, is made by the California-based company Amgen and is biosimilar to the AbbVie drug Humira (adalimumab). 

Health and Human Services (HHS) Secretary Sylvia Burwell doesn’t have much time left in her position. Her boss’s second presidential term is almost over, so her role as steward of his hallmark policy, the Affordable Care Act (ACA), will be over too. 

Physicians are faced with the proposition from paper to digital technology at a rapid pace. A study conducted by the American Medical Association (AMA) found that many physicians have common “musts” for the use of digital tool and what they expect from the digital tools in return.

Sept. 23 was the final day for insurers to confirm their health insurance exchange participation in the states relying on the federal Healthcare.gov marketplace. Last-minute decisions by two insurers will affect coverage options in Delaware, Nebraska, Pennsylvania and West Virginia. 

Obesity has become an epidemic in America and according to Bruce Lee, the healthcare industry is helping expand out waistlines.

Donald Trump has been telling supporters and reporters that President Barack Obama is trying to delay open enrollment on health insurance exchanges until after Election Day—but the start date has been set in stone for months.

PLYMOUTH MEETING, PA—In its newest analysis of patient safety errors, ECRI Institute PSO today releases a Deep Dive review of reported events involving patient identification.